Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.
BioNTech has raised its full-year revenue forecast from its record-breaking COVID-19 vaccine Comirnarty, and now expects to earn €16bn-€17bn ($19.7bn) in 2021.
That is a potential 7% uplift on its BioNTech’s previous forecast of €15.9bn, and in line with the increase its...
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
